This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medidata Solutions Experts Highlight New Approaches To Clinical Trials At Key European Pharmaceutical Conferences This Autumn

Stocks in this article: MDSO

Life science industry thought leaders from Medidata Solutions (NASDAQ: MDSO) will be addressing the changing world of clinical trials at numerous European events in the coming weeks. From Big Data’s impact on R&D to the role of cloud computing in the clinical development enterprise to data-based analytics and decision making, Medidata’s team will discuss new approaches to tackling today’s pharma industry challenges.

“The European pharma community is continuing to react to significant financial pressures, and the resolve to reduce timelines, reduce costs and maximize delivery is higher than ever,” said Richard Young, director, regional sales, EMEA at Medidata Solutions. “Medidata is leading this crusade, delivering solutions to sponsors that help them meet—and exceed—these goals. By taking a leadership role in discussing how technology can optimize the entire clinical paradigm, Medidata is contributing to the faster, more effective delivery of medicines in Europe and across the globe.”

12th International Prix Galien, Lyon, France, October 4, 2012

  • “How Big Data (and Data Privacy) will Revolutionize Life Sciences R&D,” Glen de Vries, president

DIA 6th Annual Clinical Forum, The Hague, Netherlands, October 8–10, 2012

  • “New Approaches to Validation for SaaS-based Clinical Computing Solutions in the Cloud,” Tony Hewer, senior director, quality and regulatory affairs
  • “Improving Operational Efficiency: An Approach to Centralized, Targeted Monitoring,” Marcus Thornton, director, CTMS

PhUSE Annual Conference 2012, Budapest, Hungary, October 14-17, 2012

  • “Real-World Application of the Protocol Representation Model,” Josh Pines, senior manager, product marketing
  • “Testing in the Cloud. Not Just for the Birds, but Monkeys Too,” Geoff Low, software architect
  • “New Approaches to Validation for SaaS-based Clinical Computing Solutions in the Cloud,” Tony Hewer, senior director, quality and regulatory affairs
  • “Optimizing Data Validation,” Andrew Newbigging, senior vice president, development

11th Annual Partnerships in Clinical Trials, Hamburg, Germany, November 6-9, 2012

  • “Medidata Case Study: The Key Initiatives of the Insight Council,” Steve Young, senior director, product management

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs